Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer

NCT04386057 is registered in ClinicalTrials.gov with Kimberly Perez, MD as lead sponsor.

NCT NCT04386057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04386057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
Lead sponsor
Kimberly Perez, MD
Phase
Phase 2
Overall status
Completed
Start date
May 27, 2020
Completion date
February 5, 2024
Enrollment
52 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, pancreatic cancer